Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Autophagy-based protein degradation is a promising strategy for treating diseases and developing new drugs.
• Targeting specific proteins for degradation via autophagy offers a novel therapeutic approach.

Purpose of the Study:

• To develop a novel autophagy-targeting chimera (AUTAC) capable of degrading specific proteins.
• To investigate the efficacy of AUTACs in targeting key autophagy proteins like LC3.
• To evaluate the anti-proliferative activity of the developed compounds in cancer cells.

Main Methods:

• Design and synthesis of novel autophagy-targeting chimeras (AUTACs).
• Utilizing AUTACs to target the autophagy key protein LC3 for protein degradation.
• Assessing the degradation of target proteins, such as BRD4, through the autophagy pathway.
• Evaluating the anti-proliferative effects of the lead compound in various tumor cell lines.

Main Results:

• A novel class of AUTACs was successfully developed.
• The lead compound, 10f, effectively degraded the BRD4 protein via the autophagy pathway.
• Compound 10f demonstrated significant anti-proliferative activity against multiple tumor cell types.

Conclusions:

• The developed AUTAC technology provides a powerful new approach for targeted protein degradation.
• AUTACs targeting LC3 offer a versatile platform for medicinal chemists to study disease-related targets.
• This work expands the toolbox for autophagy-based drug discovery and development.